Dose recommendations for extended half-life hemophilia factor products fall short
We, like many in the hemophilia community, were excited to see extended half-life (EHL) factor VIII and IX products start coming to market over the last few months. These products — and expected future products — promise equivalent or greater prophylactic bleeding control with fewer infusions, and so could greatly enhance patients’ quality of life.
Yet, as we noted in our recent editorial in Haemophilia, we are greatly concerned that patients …
Dose recommendations for extended half-life hemophilia factor products fall short
